EBR Systems (ASX:EBR) said that the US Centers for Medicare & Medicaid Services has proposed the approval of a new technology add-on payment for the company's WiSE cardiac resynchronization therapy system for the treatment of heart failure, according to a Tuesday filing with the Australian bourse.
If approved, the maximum add-on payment will be 65% of the device cost in addition to standard Medicare payments and will be effective for three years starting Oct. 1, the filing said.
The company plans to seek similar support for outpatient use, the filing added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。